P2Y14R antagonist 3
P2Y14R antagonist 3 (Compound A) is a potent and orally active P2Y14R antagonist with an IC50 value of 23.60 nM and a Kd value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056) -induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases[1].
Product Specifications
UNSPSC
12352005
Target
P2Y Receptor
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CNC(C1CN(CC12CCN(CC2)C(C3=NOC4=CC=CC=C43)=O)C(C5=C6C=CC=CC6=NO5)=O)=O
Molecular Formula
C26H25N5O5
Molecular Weight
487.51
References & Citations
[1]Wei Z, et al. Discovery of a potent and in vivo anti-inflammatory Efficacious, P2Y14R antagonist with a novel benzisoxazoles scaffold by DNA-encoded chemical library technology. Eur J Med Chem. 2025 Feb 27;289:117451.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
P2Y14 Receptor
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15307055 1 Vial
Lentiviral human FMO5 shRNA (UAS) - Lentiviral human FMO5 shRNA (UAS, GFP) (25)
Ask
View Details 
